Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(04): 646-656
DOI: 10.1055/a-1647-9896
Trial Protocol Design Paper

Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study

Isabelle Mahé 
1   Service de Médecine Interne, Hôpital Louis Mourier, AP-HP, Colombes, France
2   Université de Paris, Paris, France
3   Innovative Therapies in Haemostasis, INSERM UMR_S1140, Paris, France
4   INNOVTE-FCRIN, Saint-Etienne, France
,
Giancarlo Agnelli
5   Internal Vascular and Emergency Medicine – Stroke Unit, University of Perugia, Perugia, Italy
,
Cihan Ay
6   Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
,
Aristotelis Bamias 
7   2nd Propaedeutic Department of Medicine, ATTIKON University Hospital, National & Kapodistrian University of Athens, Athens, Greece
,
Cecilia Becattini
5   Internal Vascular and Emergency Medicine – Stroke Unit, University of Perugia, Perugia, Italy
,
Marc Carrier
8   Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
,
Céline Chapelle
9   Unité de Recherche Clinique Innovation et Pharmacologie, CHU de Saint-Etienne, Saint-Etienne, France
10   SAINBIOSE INSERM U1059, Université Jean Monnet, Université de Lyon, Saint-Etienne, France
,
Alexander T. Cohen
11   Guy's and St. Thomas' NHS Foundation Trust Hospital, King's College London, London, United Kingdom
,
Philippe Girard
12   Département de Pneumologie, Institut Mutualiste Montsouris, Paris, France
,
Menno V. Huisman
13   Department of Medicine − Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Frederikus A. Klok 
13   Department of Medicine − Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Juan J. López-Núñez
14   Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
15   Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Anthony Maraveyas
16   Queen's Centre for Oncology and Haematology, Hull University Teaching Hospitals NHS Trust, Hull York Medical School, Cottingham, Hull, United Kingdom
,
Didier Mayeur
17   Centre Georges-Francois Leclerc, Dijon, France
,
Olivier Mir
18   Institut Gustave-Roussy, Paris, France
,
Manuel Monreal
14   Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
15   Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
19   Universidad Católica de Murcia, Murcia, Spain
,
Marc Righini
20   Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland
,
Charles M. Samama
21   Intensive Care and Perioperative Medicine, Department of Anaesthesia, Hôpital Cochin, GHU AP-HP Centre-Université de Paris, Paris, France
,
Kostas Syrigos
22   Department of Medicine, Sotiria General Hospital, Athens School of Medicine, National & Kapodistrian University, Athens, Greece
,
Sebastian Szmit
23   Departments of Pulmonary Circulation, Thromboembolic Diseases, and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland
,
Adam Torbicki
23   Departments of Pulmonary Circulation, Thromboembolic Diseases, and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland
,
Peter Verhamme 
24   Vascular Medicine and Haemostasis, University Hospitals Leuven, Leuven, Belgium
,
Eric Vicaut
25   URC Lariboisière – Saint-Louis, AP-HP, Université de Paris, Paris, France
,
Tzu-Fei Wang
8   Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
,
Guy Meyer
2   Université de Paris, Paris, France
4   INNOVTE-FCRIN, Saint-Etienne, France
26   Hôpital Européen Georges Pompidou, APHP, Sorbonne Paris Cité, Paris, France
,
Silvy Laporte
4   INNOVTE-FCRIN, Saint-Etienne, France
9   Unité de Recherche Clinique Innovation et Pharmacologie, CHU de Saint-Etienne, Saint-Etienne, France
10   SAINBIOSE INSERM U1059, Université Jean Monnet, Université de Lyon, Saint-Etienne, France
› Author Affiliations Funding Funding for the study is provided by the BMS–Pfizer Alliance. Tablets of apixaban are provided by Bristol-Myers Squibb and are packaged under AP-HP's responsibility. Bristol-Myers Squibb and Pfizer did not have any role in the study design, study conduction, data collection, or analysis.
› Further Information
   Permissions and Reprints

Abstract

Cancer-associated thrombosis (CT) is associated with a high risk of recurrent venous thromboembolic (VTE) events that require extended anticoagulation in patients with active cancer, putting them at risk of bleeding. The aim of the API-CAT study (NCT03692065) is to assess whether a reduced-dose regimen of apixaban (2.5 mg twice daily [bid]) is noninferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent VTE in patients with active cancer who have completed ≥6 months of anticoagulant therapy for a documented index event of proximal deep-vein thrombosis and/or pulmonary embolism. API-CAT is an international, randomized, parallel-group, double-blind, noninferiority trial with blinded adjudication of outcome events. Consecutive patients are randomized to receive apixaban 2.5 or 5 mg bid for 12 months. The primary efficacy outcome is a composite of recurrent symptomatic or incidental VTE during the treatment period. The principal safety endpoint is clinically relevant bleeding, defined as a composite of major bleeding or nonmajor clinically relevant bleeding. Assuming a 12-month incidence of the primary outcome of 4% with apixaban and an upper limit of the two-sided 95% confidence interval of the hazard ratio <2.0, 1,722 patients will be randomized, assuming an up to 10% loss in total patient-years (β = 80%; α one-sided = 0.025). This trial has the potential to demonstrate that a regimen of extended treatment for patients with CT beyond an initial 6 months, with a reduced apixaban dose, has an acceptable risk of recurrent VTE recurrence and decreases the risk of bleeding.

Keywords

venous thromboembolism - cancer - apixaban - randomized

Supplementary Material



Publication History

Received: 27 May 2021

Accepted: 08 July 2021

Accepted Manuscript online:
17 September 2021

Article published online:
05 November 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
    CrossrefPubMedGoogle Scholar
  • 2 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
    CrossrefPubMedGoogle Scholar
  • 3 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 4 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (01) 7-34
    CrossrefPubMedGoogle Scholar
  • 5 Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study. Lancet 2015; 385 (9974): 1206-1218
    CrossrefPubMedGoogle Scholar
  • 6 Rosenberg JE, Hoffman-Censits J, Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387 (10031): 1909-1920
    CrossrefPubMedGoogle Scholar
  • 7 Schachter J, Ribas A, Long GV. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390 (10105): 1853-1862
    CrossrefPubMedGoogle Scholar
  • 8 Balar AV, Galsky MD, Rosenberg JE. et al; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389 (10064): 67-76
    CrossrefPubMedGoogle Scholar
  • 9 Motzer RJ, Tannir NM, McDermott DF. et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378 (14) 1277-1290
    CrossrefPubMedGoogle Scholar
  • 10 Mahé I, Plaisance L, Chapelle C. et al. Long-term treatment of cancer-associated thrombosis (CAT) beyond 6 months in the medical practice: USCAT, a 432-patient retrospective non-interventional study. Cancers (Basel) 2020; 12 (08) 2256
    CrossrefPubMedGoogle Scholar
  • 11 Schmidt RA, Al Zaki A, Desilet N. et al. Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism. Thromb Res 2020; 188: 106-114
    CrossrefPubMedGoogle Scholar
  • 12 Mahé I, Mayeur D, Krakowski I. Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations. Support Care Cancer 2016; 24 (10) 4105-4112
    CrossrefPubMedGoogle Scholar
  • 13 Cohoon KP, Ransom JE, Leibson CL. et al. Direct medical costs attributable to cancer-associated venous thromboembolism: a population-based longitudinal study. Am J Med 2016; 129: 1000.e15-1000.e25
    CrossrefPubMedGoogle Scholar
  • 14 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 van der Hulle T, den Exter PL, van den Hoven P. et al. Cohort study on the management of cancer-associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured of cancer. Chest 2016; 149 (05) 1245-1251
    CrossrefPubMedGoogle Scholar
  • 16 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 17 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
    CrossrefPubMedGoogle Scholar
  • 18 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38 (05) 496-520
    CrossrefPubMedGoogle Scholar
  • 19 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
    Google Scholar
  • 20 Francis CW, Kessler CM, Goldhaber SZ. et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015; 13 (06) 1028-1035
    CrossrefPubMedGoogle Scholar
  • 21 Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T. et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res 2017; 157: 90-96
    CrossrefPubMedGoogle Scholar
  • 22 Mahé I, Chidiac J, Bertoletti L. et al; RIETE investigators. The clinical course of venous thromboembolism may differ according to cancer site. Am J Med 2017; 130 (03) 337-347
    CrossrefPubMedGoogle Scholar
  • 23 Schaefer JK, Li M, Wu Z. et al. Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs. J Thromb Haemost 2021; 19 (01) 212-220
    CrossrefPubMedGoogle Scholar
  • 24 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 25 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedGoogle Scholar
  • 26 McBane II RD, Wysokinski WE, Le-Rademacher JG. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
    CrossrefPubMedGoogle Scholar
  • 27 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedGoogle Scholar
  • 28 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 30 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    Google Scholar
  • 31 Di Nisio M, van Es N, Carrier M. et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost 2019; 17 (11) 1866-1874
    CrossrefPubMedGoogle Scholar
  • 32 Marshall A, Levine M, Hill C. et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). J Thromb Haemost 2020; 18 (04) 905-915
    CrossrefPubMedGoogle Scholar
  • 33 Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14 (07) 1480-1483
    CrossrefPubMedGoogle Scholar
  • 34 Noble SI, Nelson A, Fitzmaurice D. et al. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technol Assess 2015; 19 (83) vii-xxiii , 1–93
    CrossrefPubMedGoogle Scholar
  • 35 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 36 The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-inferiority. Accessed July 1, 2021 at: https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-switching-between-superiority-non-inferiority_en.pdf
    PubMedGoogle Scholar
  • 37 Campigotto F, Neuberg D, Zwicker JI. Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. J Thromb Haemost 2012; 10 (07) 1449-1451
    CrossrefPubMedGoogle Scholar
  • 38 Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509
    CrossrefPubMedGoogle Scholar
  • 39 Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol 2001; 52 (03) 223-228
    CrossrefPubMedGoogle Scholar
  • 40 Lee AY, Levine MN, Baker RI. et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 41 Lee AYY, Kamphuisen PW, Meyer G. et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 42 McBane II RD, Loprinzi CL, Ashrani A. et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. Eur J Haematol 2020; 104 (02) 88-96
    CrossrefPubMedGoogle Scholar